Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent hepatitis E virus-like particle vaccine
- Development stage
- Preclinical
- Lead developer
- The University of Hong Kong
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The bivalent hepatitis E virus-like particle (VLP) vaccine is a next-generation vaccine candidate designed to provide broad-spectrum protection against both conventional human hepatitis E virus (Paslahepevirus balayani or bHEV) and the emerging zoonotic threat, rat hepatitis E virus (Rocahepevirus ratti or rHEV). Developed by researchers at the University of Hong Kong, the vaccine incorporates recombinant bHEV-A4 p239 and rHEV p241 (HEV-C1 p241) proteins expressed in Escherichia coli, which self-assemble into virus-like particles. Adjuvanted with aluminum hydroxide, this bivalent formulation elicits robust, balanced IgG antibody responses and confers complete cross-species protection against both bHEV and rHEV challenges in animal models.
- Other names
- bHEV/rHEV bivalent vaccinebHEV/rHEV bivalent vaccine candidatebivalent bHEV/rHEV VLP vaccinebivalent hepatitis E VLP vaccinebivalent HEV VLP vaccine
02
Targets
HEV ORF2 (Hepatitis E virus capsid protein)
Beyond the preview
Go deeper on bivalent hepatitis E virus-like particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent hepatitis E virus-like particle vaccine.